TF and muscular dystrophy: In this study, either monoclonal antibodies or fragment antibodies targeting transferrin are conjugated to the oligonucleotides (oral presentations from Dyne Therapeutics and Avidity BioScience at the annual Parent Project Muscular Dystrophy conference, June 2022).